Roche files Actemra for prevention of joint damage in US
This article was originally published in Scrip
Executive Summary
Genentech (Roche) has submitted a supplemental BLA to the US FDA for its first-in-class interleukin-6 inhibitor Actemra (tocilizumab) for an indication of prevention of structural joint damage and improvement of physical function in adults with moderately to severely active rheumatoid arthritis (RA).